July 12, 2021 07:47 AM EDT
Deals

Branch­ing out from di­a­betes? No­vo Nordisk shells out the big bucks for Prothena's AT­TR amy­loi­do­sis pipeline

Max Gelman

Senior Editor

Os­ten­si­bly look­ing to branch out from its di­a­betes fran­chis­es, No­vo Nordisk is mak­ing a ma­jor play in­to the amy­loid space — and pay­ing a pret­ty pen­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times